JP2004537581A5 - - Google Patents

Download PDF

Info

Publication number
JP2004537581A5
JP2004537581A5 JP2003518580A JP2003518580A JP2004537581A5 JP 2004537581 A5 JP2004537581 A5 JP 2004537581A5 JP 2003518580 A JP2003518580 A JP 2003518580A JP 2003518580 A JP2003518580 A JP 2003518580A JP 2004537581 A5 JP2004537581 A5 JP 2004537581A5
Authority
JP
Japan
Prior art keywords
acid
alanine
arginine
derivative
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003518580A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004537581A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2002/026796 external-priority patent/WO2003013574A1/en
Publication of JP2004537581A publication Critical patent/JP2004537581A/ja
Publication of JP2004537581A5 publication Critical patent/JP2004537581A5/ja
Pending legal-status Critical Current

Links

JP2003518580A 2001-08-08 2002-08-02 メラニン濃縮ホルモン拮抗物質 Pending JP2004537581A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31092801P 2001-08-08 2001-08-08
PCT/US2002/026796 WO2003013574A1 (en) 2001-08-08 2002-08-02 Melanin-concentrating hormone antagonists

Publications (2)

Publication Number Publication Date
JP2004537581A JP2004537581A (ja) 2004-12-16
JP2004537581A5 true JP2004537581A5 (enExample) 2005-12-22

Family

ID=23204651

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003518580A Pending JP2004537581A (ja) 2001-08-08 2002-08-02 メラニン濃縮ホルモン拮抗物質

Country Status (5)

Country Link
US (1) US7335723B2 (enExample)
EP (1) EP1416951A1 (enExample)
JP (1) JP2004537581A (enExample)
CA (1) CA2456964A1 (enExample)
WO (1) WO2003013574A1 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002352878B2 (en) 2001-11-27 2007-11-22 Merck Sharp & Dohme Corp. 2-Aminoquinoline compounds
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
WO2005097127A2 (en) 2004-04-02 2005-10-20 Merck & Co., Inc. Method of treating men with metabolic and anthropometric disorders
CN103601792B (zh) 2007-06-04 2016-06-29 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
ES2624828T3 (es) 2008-07-16 2017-07-17 Synergy Pharmaceuticals Inc. Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
CA2741672A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
SG192941A1 (en) 2011-02-25 2013-09-30 Merck Sharp & Dohme Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents
KR20150036245A (ko) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 항당뇨병 트리시클릭 화합물
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
EP2970119B1 (en) 2013-03-14 2021-11-03 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP4424697A3 (en) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US20170056352A1 (en) 2015-08-25 2017-03-02 Rgenix, Inc. PHARMACEUTICALLY ACCEPTABLE SALTS OF beta-GUANIDINOPROPIONIC ACID WITH IMPROVED PROPERTIES AND USES THEREOF
RU2694050C1 (ru) 2015-10-23 2019-07-09 Фуджифилм Корпорэйшн Циклический пептид, подложка для аффинной хроматографии, меченое антитело, конъюгат антитела и лекарственного средства и фармацевтический препарат
WO2017069269A1 (ja) * 2015-10-23 2017-04-27 富士フイルム株式会社 環状ペプチド、アフィニティクロマトグラフィー担体、標識化抗体、抗体薬物複合体、および医薬製剤
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
WO2018160178A1 (en) 2017-03-01 2018-09-07 Rgenix, Inc. Pharmaceutically acceptable salts of b-guanidinopropionic acid with improved properties and uses thereof
WO2021119316A1 (en) 2019-12-11 2021-06-17 Rgenix, Inc. Methods of treating cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5049655A (en) * 1989-03-22 1991-09-17 The Salk Institute For Biological Studies Melanin-concentrating hormones
US5849708A (en) * 1995-06-06 1998-12-15 Joslin Diabetes Center, Inc. Promotion of eating behavior
CA2399509A1 (en) 2000-02-03 2001-08-09 Merck & Co., Inc. Melanin-concentrating hormone analogs
JP2004537521A (ja) 2001-05-31 2004-12-16 メルク エンド カムパニー インコーポレーテッド メラニン濃縮ホルモン類似体
CA2473229A1 (en) 2002-01-09 2003-07-24 Merck & Co., Inc. Selective melanin-concentrating hormone type -1 receptor agonists

Similar Documents

Publication Publication Date Title
JP2004537581A5 (enExample)
JP2002523466A5 (enExample)
JP2010536714A5 (enExample)
JP2013533864A5 (enExample)
KR970042553A (ko) 캠프토테신 유도체
KR101328851B1 (ko) 개선된 특성을 가지는 재구성된 계면활성제
CN102300580A (zh) 二肽连接的药剂
JP2011511753A5 (enExample)
JP2004521123A5 (enExample)
JP2002526454A5 (enExample)
JP2015532283A5 (enExample)
JP2013500990A5 (enExample)
JP2020502051A5 (enExample)
JP2007523881A5 (enExample)
JP2011508742A5 (enExample)
HRP20161614T1 (hr) Terapijska sredstva za smanjenje razina paratiroidnog hormona
CA2121724A1 (en) Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction
JP2024520861A (ja) 遺伝性ヘモクロマトーシスの治療のためのヘプシジン模倣体
EP3074032B1 (en) Fatty acid derivatives of dimeric inhibitors of psd-95
JP2011523935A5 (enExample)
RU2010111139A (ru) Комбинированная терапия рака поджелудочной железы с использованием антигенного пептида и химиотерапевтического средства
JPH0773479B2 (ja) 栄養素組成物
JP2009533355A5 (enExample)
JP2004535461A5 (enExample)
JP7751641B2 (ja) Glp-1/glp-2デュアルアゴニストの医薬組成物